Comparative Pharmacology
Head-to-head clinical analysis: DYANAVEL XR 5 versus MYDAYIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYANAVEL XR 5 versus MYDAYIS.
DYANAVEL XR 5 vs MYDAYIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CNS stimulant; blocks reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their synaptic concentrations.
MYDAYIS is a fixed-dose combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mechanism of action in ADHD is not fully elucidated, but they block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase their release into the extraneuronal space.
20 mg orally once daily in the morning; may increase by 10 mg weekly based on response; maximum 60 mg/day.
Oral, 12.5 mg or 25 mg once daily in the morning.
None Documented
None Documented
Terminal elimination half-life for d-amphetamine is 10-13 hours; for l-amphetamine, 13-16 hours. Clinical context: Twice-daily dosing may be required for sustained effect.
12 hours for d-methylphenidate; 3-4 hours for l-methylphenidate; clinical context: d-isomer provides extended coverage; l-isomer contributes minimal activity
Renal: ~90% as unchanged amphetamine and metabolites. Fecal: minimal (<5%).
Renal (approx. 90% as unchanged drug and 10% as inactive metabolites); fecal <5%
Category C
Category C
CNS Stimulant
CNS Stimulant